Citation only
via Europe PMC
The microbiome-mitochondria axis: the context-dependent role of urolithin A in aging and cancer via mitophagy.
Wu J, Ye X, Hua W, Yao Y, Sun L, Ma H, Yu C, Cheng Y, Mi S.
Molecular biology reports · 2026
Dysbiosis
Deregulated nutrient-sensing
Mitochondrial dysfunction
Altered intercellular communication
Chronic inflammation
Disabled macroautophagy
Human
Preclinical / animal
Review
Abstract
Urolithin A (UA) is a gut microbiota-derived metabolite formed from dietary ellagitannins and ellagic acid. It has drawn sustained interest because it can influence mitochondrial quality control, but the evidence does not support a simple anti-aging or anticancer label. In this review, UA is examined across microbial metabolism, urolithin metabotypes, pharmacokinetic exposure, mitophagy biology, aging-related phenotypes, and cancer. The emphasis is placed on what has been shown, what remains model-dependent, and where translational claims are still premature. Preclinical work links UA to PINK1/Parkin-, TFEB-, AMPK-, sirtuin-, and Nrf2-associated pathways, with reported improvements in mitochondrial turnover and inflammatory signaling. Human data are narrower: most trials have been short and have focused on safety, muscle performance, mitochondrial signatures, and circulating biomarkers. Evidence for cancer prevention or cancer therapy still comes mainly from cell and animal studies. Because mitophagy can limit early mitochondrial damage but may also help established tumors survive hypoxia, nutrient restriction, dormancy, and therapy-induced stress, UA is better regarded as a microbiome-dependent mitochondrial modulator whose effects depend on biological setting. The next step is to define direct molecular targets, test native and conjugated UA at human-relevant exposure ranges, account for UM-A, UM-B, and UM-0 metabotypes, and evaluate cancer-specific endpoints before making therapeutic claims.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.1007/s11033-026-12542-y
- Canonical
- link ↗
- Fetched
- 2026-10-08 MST
Cite this
APA
J, W., X, Y., W, H., Y, Y., L, S., H, M., C, Y., Y, C., & S., M. (2026). The microbiome-mitochondria axis: the context-dependent role of urolithin A in aging and cancer via mitophagy. <em>Molecular biology reports</em>. https://doi.org/10.1007/s11033-026-12542-y
Vancouver
J W, X Y, W H, Y Y, L S, H M, et al. The microbiome-mitochondria axis: the context-dependent role of urolithin A in aging and cancer via mitophagy. Molecular biology reports. 2026. doi:10.1007/s11033-026-12542-y.
BibTeX
@article{wu2026Themic,
title = {The microbiome-mitochondria axis: the context-dependent role of urolithin A in aging and cancer via mitophagy.},
author = {Wu J and Ye X and Hua W and Yao Y and Sun L and Ma H and Yu C and Cheng Y and Mi S.},
journal = {Molecular biology reports},
year = {2026},
doi = {10.1007/s11033-026-12542-y},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in aging 2026
Open access · OA
Gut microbiota-epigenetic interactions in systemic aging: mechanistic drivers for endocrine and reproductive network remodeling and therapeutic modulation.
Nature Medicine 2024
Open access · OA
Validation of biomarkers of aging
International Journal of Molecular Sciences 2022
Open access · CC-BY
Influence of Foods and Nutrition on the Gut Microbiome and Implications for Intestinal Health
Frontiers in aging 2026
Open access · OA
Narrative review of intravenous NAD<sup>+</sup> and NAD<sup>+</sup> precursors in wellness and translational medicine.
Frontiers in Nutrition 2026
Open access · CC-BY
Urolithins in clinical translation: from gut microbial metabolites to precision interventions
Cell Stress 2023
Open access · CC-BY